NASDAQ:IRIX - IRIDEX Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.75 +0.07 (+2.61 %) (As of 01/29/2020 06:00 AM ET) Add Compare Today's Range$2.62Now: $2.75▼$2.7750-Day Range$2.17MA: $2.60▼$3.5152-Week Range$1.50Now: $2.75▼$5.69Volume23,200 shsAverage Volume105,397 shsMarket Capitalization$37.90 millionP/E RatioN/ADividend YieldN/ABeta0.87 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:IRIX Previous Symbol CUSIPN/A CIK1006045 Webhttp://www.iridex.com/ Phone650-940-4700Debt Debt-to-Equity Ratio0.09 Current Ratio3.36 Quick Ratio2.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.60 million Price / Sales0.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book1.25Profitability EPS (Most Recent Fiscal Year)($1.05) Net Income$-12,810,000.00 Net Margins-23.42% Return on Equity-37.78% Return on Assets-25.79%Miscellaneous EmployeesN/A Outstanding Shares13,780,000Market Cap$37.90 million Next Earnings Date3/3/2020 (Estimated) OptionableNot Optionable Receive IRIX News and Ratings via Email Sign-up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IRIX Rates by TradingView IRIDEX (NASDAQ:IRIX) Frequently Asked Questions What is IRIDEX's stock symbol? IRIDEX trades on the NASDAQ under the ticker symbol "IRIX." How were IRIDEX's earnings last quarter? IRIDEX Co. (NASDAQ:IRIX) issued its earnings results on Thursday, November, 7th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.05. The medical equipment provider earned $10.66 million during the quarter, compared to analyst estimates of $10.08 million. IRIDEX had a negative return on equity of 37.78% and a negative net margin of 23.42%. View IRIDEX's Earnings History. When is IRIDEX's next earnings date? IRIDEX is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for IRIDEX. What guidance has IRIDEX issued on next quarter's earnings? IRIDEX issued an update on its fourth quarter 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.6-11.8 million, compared to the consensus revenue estimate of $10.88 million. What is the consensus analysts' recommendation for IRIDEX? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX. Has IRIDEX been receiving favorable news coverage? News coverage about IRIX stock has trended very negative recently, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IRIDEX earned a news impact score of -3.3 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for IRIDEX. Are investors shorting IRIDEX? IRIDEX saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 89,500 shares, an increase of 5.7% from the December 31st total of 84,700 shares. Based on an average daily trading volume, of 62,100 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.8% of the company's shares are sold short. View IRIDEX's Current Options Chain. Who are some of IRIDEX's key competitors? Some companies that are related to IRIDEX include Fonar (FONR), BioSig Technologies (BSGM), Edap Tms (EDAP), Second Sight Medical Products (EYES), Fc Global Realty (FCRE), electroCore (ECOR), Helius Medical Technologies (HSDT), Precision Optics (PEYE), ENDRA Life Sciences (NDRA), Digirad (DRAD), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), Nexeon Medsystems (NXNN), Reshape Lifesciences (RSLS) and CHF Solutions (CHFS). What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include SCYNEXIS (SCYX), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), CTI BioPharma (CTIC), Gilead Sciences (GILD), Trevena (TRVN), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Capstone Turbine (CPST) and Fate Therapeutics (FATE). Who are IRIDEX's key executives? IRIDEX's management team includes the folowing people: Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)Mr. Romeo R. Dizon, VP of Fin.Ms. Leigh Salvo, Head of Investor RelationsMr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44) How do I buy shares of IRIDEX? Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is IRIDEX's stock price today? One share of IRIX stock can currently be purchased for approximately $2.75. How big of a company is IRIDEX? IRIDEX has a market capitalization of $37.90 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. View Additional Information About IRIDEX. What is IRIDEX's official website? The official website for IRIDEX is http://www.iridex.com/. How can I contact IRIDEX? IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected] MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 175 (Vote Outperform)Underperform Votes: 172 (Vote Underperform)Total Votes: 347MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: What are the benefits of a portfolio tracker?
